We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+42.48%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$228M
AUM Growth
+$9.22M
Cap. Flow
-$20.8M
Cap. Flow %
-9.11%
Top 10 Hldgs %
62.39%
Holding
90
New
18
Increased
18
Reduced
19
Closed
27

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$13.7M
2
MRK icon
Merck
MRK
+$9.87M
3
DHR icon
Danaher
DHR
+$3.66M
4
SNY icon
Sanofi
SNY
+$2.9M
5
MDT icon
Medtronic
MDT
+$2.48M

Top Sells

Rank Stock Value
1
QCP
Quality Care Properties, Inc.
QCP
+$23.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.94M
3
AERI
Aerie Pharmaceuticals
AERI
+$6.83M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.25M
5
NVRO
NEVRO CORP.
NVRO
+$3.78M

Sector Composition

Rank Sector Weight
1 Healthcare 78.99%
2 Miscellaneous 12.59%
3 Industrials 7.51%
4 Communication Services 0.5%
5 Real Estate 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$26.2M 11.48%
90,000
+60,000
+200% +$17.1M
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$20.8M 9.13%
419,279
+268,434
+178% +$13.7M
RCM
3
DELISTED
R1 RCM Inc. Common Stock
RCM
$17.1M 7.51%
1,685,087
-122,989
-7% -$1.12M
AMRN
4
Amarin Corp
AMRN
$295M
$16.2M 7.11%
49,785
+26,785
+116% +$2.02M
SNY icon
5
Sanofi
SNY
$107B
$12.5M 5.51%
280,872
+67,900
+32% +$2.9M
GSK icon
6
GSK
GSK
$102B
$11.7M 5.15%
231,427
+29,360
+15% +$1.49M
MRK icon
7
Merck
MRK
$366B
$10.6M 4.63%
+154,894
New +$9.87M
RDUS
8
DELISTED
Radius Health, Inc.
RDUS
$9.42M 4.13%
528,992
+60,411
+13% +$1.37M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$137B
$9.27M 4.07%
48,092
+13,270
+38% +$2.36M
TLGT
10
DELISTED
Teligent, Inc
TLGT
$8.34M 3.66%
211,210
– –
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
$7.43M 3.26%
120,711
-106,191
-47% -$6.83M
SRPT icon
12
Sarepta Therapeutics
SRPT
$2.2B
$6.81M 2.99%
42,194
+2,194
+5% +$300K
SAGE
13
DELISTED
Sage Therapeutics
SAGE
$6.16M 2.7%
43,621
+220
+0.5% +$34K
ABT icon
14
Abbott
ABT
$195B
$5.51M 2.42%
75,100
+29,200
+64% +$1.92M
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.49M 2.41%
119,371
-14,780
-11% -$599K
ENSG icon
16
The Ensign Group
ENSG
$10.1B
$5.11M 2.24%
143,946
-33,594
-19% -$1.17M
DHR icon
17
Danaher
DHR
$152B
$3.87M 1.7%
+40,161
New +$3.66M
XENE icon
18
Xenon Pharmaceuticals
XENE
$5.81B
$2.77M 1.22%
+209,739
New +$2.43M
MDT icon
19
Medtronic
MDT
$117B
$2.65M 1.16%
+26,800
New +$2.48M
ANAB icon
20
AnaptysBio
ANAB
$1.67B
$2.25M 0.99%
22,524
-10,110
-31% -$839K
MDGL icon
21
Madrigal Pharmaceuticals
MDGL
$12.3B
$2.01M 0.88%
9,400
+4,900
+109% +$1.23M
WMGI
22
DELISTED
Wright Medical Group Inc
WMGI
$1.93M 0.85%
+66,600
New +$1.79M
AFMD
23
DELISTED
Affimed
AFMD
$1.88M 0.83%
43,273
+4,587
+12% +$130K
ARGX icon
24
argenx
ARGX
$64B
$1.79M 0.78%
23,554
-830
-3% -$73.6K
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
$1.78M 0.78%
100,295
+1,900
+2% +$35.1K
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2018 Portfolio in Review

As of Q3 2018, Eversept Partners held 90 positions worth $228M, up 4.2% from $219M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Eversept Partners withdrew a net $20.8M in Q3 2018, closing 27 positions and reducing 19 holdings. Its most notable exit was Quality Care Properties, Inc., an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Merck worth $10.6M.

  • Eversept Partners's largest Q3 2018 buy was Merck: 154,894 shares worth $10.6M.
  • Eversept Partners added most to Zogenix, Inc. in Q3 2018, an estimated $13.7M increase.
  • Eversept Partners's biggest Q3 2018 reduction was Aerie Pharmaceuticals, cutting an estimated $6.83M.
  • Eversept Partners fully exited Quality Care Properties, Inc. in Q3 2018, selling an estimated $23.1M.
  • Eversept Partners's ten largest holdings make up 62% of its $228M portfolio in Q3 2018.
  • Eversept Partners opened 18 new positions and closed 27 in Q3 2018.
  • Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $228M.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.